Novo Nordisk (NOVO) AGM 2024 summary

Opening remarks and agenda

• Hybrid AGM enabled in-person and virtual participation; shareholders were encouraged to submit proxies or votes by correspondence in advance.

Financial performance review

• Helge Lund described 2023 as an exceptional year for innovation, growth, value creation and impact; more than 40 million patients reached globally, the highest in the 100-year history.

Board and executive committee updates

• Helge Lund was re-elected chair and Henrik Poulsen vice chair; Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, Kasim Kutay and Martin Mackay were re-elected as directors.

• Committee appointments included Helge Lund as People and Governance Committee chair, Henrik Poulsen as Remuneration Committee chair, Laurence Debroux as Audit Committee chair and Martin Mackay as Research & Development Committee chair.

• Employee representatives Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen and Thomas Rantzau served on the Remuneration, Research & Development, Audit and People and Governance committees, respectively.